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A B S T R A C T
The brain histaminergic and dopaminergic systems closely interact, and some evidence also suggests significant
involvement of histamine in Parkinson’s disease (PD), where dopaminergic neurons degenerate. To further in-
vestigate histamine-dopamine interactions, particularly in the context of PD, a genetic lack of histamine and a
mouse model of PD and levodopa-induced dyskinesia were here combined. Dopaminergic lesions were induced
in histidine decarboxylase knockout and wildtype mice by 6-hydroxydopamine injections into the medial
forebrain bundle. Post-lesion motor dysfunction was studied by measuring drug-induced rotational behavior and
dyskinesia. Striatal tissue from both lesioned and naïve animals was used to investigate dopaminergic, ser-
otonergic and histaminergic biomarkers. Histamine deficiency increased amphetamine-induced rotation but did
not affect levodopa-induced dyskinesia. qPCR measurements revealed increased striatal expression of D1 and D2
receptor, DARPP-32, and H3 receptor mRNA, and synaptosomal release experiments in naïve mice indicated
increased dopamine release. A lack of histamine thus causes pre- and postsynaptic upregulation of striatal do-
paminergic neurotransmission which may be reflected in post-lesion motor behavior. Disturbances or manip-
ulations of the histaminergic system may thus have significant consequences for dopaminergic neurotransmis-
sion and motor behavior in both healthy and disease conditions. The findings also represent new evidence for the
complex interplay between dopamine and histamine within the nigrostriatal pathway.
1. Introduction
In Parkinson’s disease (PD), motor impairment is caused primarily
by the death of dopaminergic neurons in the substantia nigra pars
compacta (SNc) and the subsequent loss of striatal dopamine, although
other neurotransmitter systems are affected as well [1]. An effective
treatment for the motor symptoms is the dopamine precursor 3,4-di-
hydroxy-L-phenylalanine, or levodopa [1]. However, the development
of motor complications, such as abnormal involuntary movements
called levodopa-induced dyskinesia (LID), often complicates treatment
[2]. Abnormalities in striatal dopaminergic neurotransmission re-
present the main mechanism of LID, but other neurotransmitter systems
are also involved [2].
Abundant evidence from animal models suggests complex interac-
tions between the dopaminergic and histaminergic systems within the
basal ganglia [3]. Furthermore, human nigral histaminergic fibers are
in close contact with dopaminergic neurons and show increased
innervation and changed morphology in PD [4]. Higher blood and brain
levels of histamine and increased histamine H3 receptor (H3R) ex-
pression have also been reported in PD patients [5–7]. Finally, treat-
ments with a histamine H2 receptor (H2R) antagonist and a H3R ago-
nist attenuated levodopa-induced abnormal movements in rodent and
primate models of PD [8–11].
As the role of central histamine in healthy and especially disease
states is still quite unknown, the histaminergic system can thus be seen
as a promising but mostly uninvestigated research avenue in the context
of PD. Here, a complete lack of endogenous histamine and a parkin-
sonian mouse model were combined to investigate the role of the his-
taminergic system in PD and LID. This was achieved by utilizing a
mouse line [12] lacking the histamine-synthesizing enzyme histidine
decarboxylase (HDC) along with lesioning of the nigrostriatal dopa-
minergic pathway by intracerebral 6-hydroxydopamine (6−OHDA)
injections. The consequences of the histamine deficiency to post-lesion
motor behavior were studied by measuring drug-induced rotational
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behavior and LID. Striatal tissue from lesioned animals was then used to
measure the mRNA of biomarkers of the dopaminergic system (dopa-
mine receptors 1–2 and DARPP-32, a major postsynaptic signaling
molecule), the histaminergic system (the H3R, particularly important in
the striatum and in histamine-dopamine interactions [3]), and the
serotonergic system (the 5-HT2A receptor, serotonin being involved in
the mechanisms of LID [2]). Finally, striatal synaptosomes from naïve
animals were used to measure presynaptic dopamine release.
2. Materials and methods
2.1. Animals
Adult (21–27 weeks) female HDC knockout (HDC KO) mice [12]
and their wildtype (WT) littermates, fully backcrossed to C57BL/6,
were group housed in a temperature- and humidity-controlled en-
vironment under a 12 h light/dark cycle. 11 KO and 14 WT mice were
used for lesioning, and 6 KO and 5 WT mice for synaptosomal experi-
ments. Experiments were conducted according to the 3R principles of
the EU directive 2010/63/EU governing experimental animals and to
local regulations, and authorized by the Animal Experiment Board of
Finland.
2.2. Mouse model of Parkinson’s disease and levodopa-induced dyskinesia
Unilateral nigrostriatal lesions were induced as described previously
[13]. In brief, 3 μg 6−OHDA (Sigma-Aldrich, St. Louis, MO) was ad-
ministered in a stereotactic surgery into the medial forebrain bundle
(MFB) at the following coordinates: A/P – 1.2, M/L –1.1, D/V–5.0.
Desipramine pretreatment was not used. Mice received two weeks of
intensive postoperative care [13]. Four mice (2 KO, 2 WT) either died
during surgery or were euthanized due to poor condition.
Three weeks after surgery, rotations induced by the dopaminergic
drugs amphetamine (2.5 mg/kg, i.p.; Faculty of Pharmacy, University of
Helsinki, Finland) and, a week later, apomorphine (0.5 mg/kg, i.p.;
Sigma-Aldrich) were measured as described previously [14]. In brief, a
modified automatic detector system (Roto-Rat, Med Associates, St. Al-
bans, VA) was used to measure rotations at 5min intervals. Net ipsi- or
contralateral rotations were used in data analysis.
Beginning a week after the rotametry, mice were administered (s.c.)
levodopa (4.5 mg/kg; Sigma-Aldrich) and benserazide (1.125mg/kg;
Sigma-Aldrich) once per weekday. After two weeks, the mice were in-
dividually recorded for 1min at 20, 40, 60 and 80min after the levo-
dopa injection in transparent cylinders flanked by two vertical mirrors.
Dyskinesia severity was assessed from randomized recordings in a
blinded fashion using previously described scoring criteria [15]. Briefly,
dyskinetic behaviors were classified into axial, orolingual and forelimb
dyskinesia and rated on a scale of 0–4.
2.3. Ex vivo assays
Lesioned mice were killed with cervical dislocation 3 h after the last
levodopa injection. To assess the extent of dopaminergic denervation,
the posterior part of the brain was fixed overnight in 4 % paraf-
ormaldehyde in PBS, stored in 20 % sucrose in PBS at +4 °C, and used
for tyrosine hydroxylase (TH) immunohistochemistry in 30 μm free-
floating coronal brain sections as described previously [16] with the
exception that the secondary antibody was replaced with biotinylated
protein A. Stained sections were imaged using a 3DHISTECH slide
scanner (3DHISTECH, Budapest, Hungary), and optical density across
the SNc was measured as described previously [15]. Results were ex-
pressed as percent of intact side, and the lesion extent for each mouse
was calculated as the mean of three consecutive sections.
In the same lesioned mice, tissue samples from the dorsal striatum
of both hemispheres were used for qPCR assays of mRNA for the do-
pamine 1 receptor (D1R), dopamine 2 receptor (D2R), dopamine- and
cAMP-regulated phosphoprotein, 32-kDa (DARPP-32), H3R and the
serotonin 5-HT2A receptor as described previously [14]. The following
TaqMan hydrolysis probes (Applied Biosystems, Foster City, CA) were
used: D1R, Mm02620146_s1; D2R, Mm00438545_m1; DARPP-32,
Mm00454892_m1; H3R, Mm00446706_m1; 5-HT2A,
Mm00555764_m1. GAPDH (Mm99999915_g1) and PPIA
(Mm02342430_g1) were used as reference genes.
For synaptosomal [3H]dopamine release studies, fresh striatal tissue
was collected from naïve mice. Preparation of striatal synaptosomes,
uptake of [3H]dopamine (PerkinElmer, Waltham, MA), superfusion of
synaptosomes for 10min, collection of 10 s superfusate fractions, and
measurement of released radioactivity were performed as described
previously [17], with the exception that nomifensine was not added to
the superfusion buffer. Release was stimulated for 20 s by either adding
amphetamine (0.5 or 10 μM) to the superfusion buffer or, to study
depolarization-stimulated release, raising its KCl concentration to
20mM. Release data were analyzed as previously described [15].
2.4. Statistical analysis
Statistical analyses were performed using GraphPad Prism 8
(GraphPad Software, San Diego, CA). Rotametry and LID data were
analyzed with repeated measures analyses of variance (RM ANOVA)
with Greenhouse-Geisser correction (sphericity not assumed) and
Sidak’s post hoc tests. Data from qPCR and optical density measure-
ments were analyzed with two-way ANOVA. Results of [3H]dopamine
release from striatal synaptosomes were analyzed with two-way
ANOVA and an unpaired t-test.
3. Results
3.1. Immunohistochemical characterization of SNc dopaminergic lesions
Optical density measurements in midbrain sections immunostained
for TH were used to quantify the extent of dopaminergic neurodegen-
eration in the SNc (Fig. 1). Three WT and one KO mice were excluded
from all data analyses due to unsuccessful lesioning (defined as more
than 33 % SNc TH remaining). Lesion extent did not differ between
HDC KO and WT mice.
3.2. Drug-induced rotational behavior and dyskinesia in histamine-deficient
mice
To evaluate differences in hemiparkinsonian motor imbalance be-
tween unilaterally lesioned HDC KO and WT mice, rotations induced by
indirect and direct dopaminergic agonists (amphetamine and apomor-
phine, respectively) were measured (Fig. 2A). Amphetamine-induced
rotational behavior was significantly increased in HDC KO mice (gen-
otype effect: F1,15= 9.023, p= 0.0089; genotype x time interaction:
F17,255= 2.258, p=0.0036). However, apomorphine-induced rota-
tional behavior did not significantly differ between genotypes. Subse-
quently, abnormal movements induced by repeated levodopa admin-
istration were measured to evaluate any differences in LID expression
(Fig. 2B). One successfully lesioned KO mice was excluded due to not
developing dyskinesia. No statistically significant genotype differences
in dyskinesia severity were observed.
3.3. Biomarkers of neurotransmitter function in histamine-deficient mice
mRNA expression was measured with qPCR from striatal tissue
samples from unilaterally lesioned mice (Fig. 3A). The expression of
four of the investigated markers (D1R, D2R, DARPP-32, H3R) was
significantly increased in HDC KO mice (D1R genotype effect:
F1,30= 5.45, p= 0.0264; D2R genotype effect: F1,30= 4.69,
p=0.0384; DARPP-32 genotype effect: F1,06= 6.050, p=0.0203;
H3R genotype effect: F1,30= 5.902, p=0.0213). 5-HT2A mRNA was
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expressed similarly between genotypes. The dopaminergic lesion had
no statistically significant effects on mRNA expression.
Striatal synaptosomes from naїve HDC KO and WT mice were used
to study both amphetamine-induced and depolarization-stimulated re-
lease of [3H]dopamine. Depolarization-stimulated [3H]dopamine re-
lease (Fig. 3B) was significantly increased in HDC KO animals (t
(9)= 3.382, p= 0.0081), but neither half-maximal (0.5 μM) nor max-
imal (10 μM) amphetamine-induced [3H]dopamine release (Fig. 3C)
differed between HDC KO and WT mice.
4. Discussion
The histaminergic and dopaminergic systems interact closely within
the basal ganglia, and the histaminergic system could play a significant
role in conditions of dopaminergic dysfunction such as Parkinson’s
disease and levodopa-induced dyskinesia [3–7]. Here, the role of his-
tamine in PD and LID was studied by investigating the consequences of
a lack of endogenous histamine in conditions of dopaminergic de-
nervation. The genetic lack of histamine was found to be associated
with altered post-lesion motor behavior as well as the upregulation of
striatal markers of pre- and postsynaptic neurotransmitter function.
Post-lesion dopaminergic motor dysfunction was assessed by mea-
surements of drug-induced rotation (motor imbalance) and LID.
Amphetamine was found to induce more rotations in HDC KO mice
when compared to wildtype mice. Such a genotype difference in rota-
tion could indicate a difference in lesion extent [18]; however, no dif-
ference was found in TH-positive immunostaining remaining in the
SNc. The present behavioral observation is in line with some previous
Fig. 1. Extent of dopaminergic denervation
in the 6-hydroxydopamine model. A: A re-
presentative section, immunostained for tyr-
osine hydroxylase, showing a typical lesion of
the ventral midbrain dopaminergic areas
achieved with a 6−OHDA injection into the
medial forebrain bundle. B: Quantification of
the remaining SNc immunostaining in wild-
type and HDC KO mice. Mean optical
density+ SEM shown, nWT=9, nKO=8.
Fig. 2. Behavioral characterization of hemiparkinsonian HDC KOmice. A: Rotational behavior induced by amphetamine (2.5mg/kg) and apomorphine (0.5 mg/
kg) in mice with unilateral dopaminergic lesions. Amphetamine-induced rotations were increased in HDC KO mice, while there was no difference between genotypes
in apomorphine-induced rotations. Mean rotations per 5min ± SEM shown, nWT= 9 nKO= 8; 2-way RM ANOVA; *p < 0.05, **p < 0.01, Sidak’s post hoc tests. B:
Dyskinesia scores after two weeks of levodopa administration in mice with unilateral dopaminergic lesions. Dyskinesia severity did not differ between genotypes.
Mean dyskinesia scores ± SEM shown, nWT=9 nKO= 7.
S.K. Koski, et al. Neuroscience Letters 729 (2020) 134932
3
studies using unlesioned mice: methamphetamine has been reported to
induce more locomotor activity in HDC KO than wildtype mice [19,20].
However, other studies have observed attenuated [21] or unchanged
[22] amphetamine-induced motor activity in unlesioned HDC KO mice.
Previous literature thus, while conflicting, suggests that the pre-
sently observed genotype difference in amphetamine-induced motor
behavior may not be exclusive to conditions of dopaminergic de-
nervation. However, the alterations underlying this difference may be
exacerbated in conditions of dopaminergic denervation, possibly ex-
plaining the contrasting findings in unlesioned mice in some studies,
one of which [22] notably used the same mouse line as the present
study. The specific nature of these alterations or how they are caused by
the lack of histamine remains unclear, but elevated nigrostriatal
dopaminergic function could play a role. This is suggested by the pre-
sent findings of upregulation in markers of the dopaminergic system
along with previous findings in HDC KO mice such as increased in vivo
basal dopamine levels [23] and increased dopamine tissue concentra-
tions after a methamphetamine challenge [19].
The lack of histamine had no effect on apomorphine-induced rota-
tions. The effects of apomorphine have not to our knowledge been
previously studied in mice completely lacking histamine. However,
previous studies have found that drug-induced histamine depletion can
attenuate apomorphine-induced rotations in 6−OHDA-lesioned rats
[24,25]. It is possible that in the genetic model of histamine deficiency,
compensatory mechanisms are masking differences in apomorphine-
induced behavior that are revealed by pharmacologically induced his-
tamine depletion.
Dyskinetic behaviors induced by repeated levodopa administration
were, to our knowledge, here measured for the first time in mice lacking
endogenous histamine. We hypothesized that LID would be altered in
histamine-deficient mice on the basis of the abundant interactions be-
tween the histaminergic and dopaminergic systems [3], the LID-redu-
cing effects of H2R and H3R ligands in animal models [8–11], and the
ability of striatal histaminergic fibers to release levodopa-derived do-
pamine [26]. Surprisingly, dyskinesia did not differ between genotypes,
despite evidence for postsynaptic dopaminergic upregulation in the
same HDC KO mice. While the reason for this discrepancy is unknown,
LID is also influenced by many neurotransmitter systems other than
dopamine [2] that were not investigated here. Also note that different
6−OHDA models vary in their characteristics and potential applica-
tions [18]. It could be of interest to study LID also in histamine-lacking
mice treated with intrastriatal 6−OHDA, a model where the extent and
topography of dopaminergic neurodegeneration is markedly more re-
stricted.
Significant upregulation of a number of biochemical dopaminergic
markers was observed in the histamine-deficient mice. In lesioned HDC
KO mice, qPCR assays revealed elevated striatal expression of D1R, D2R
and DARPP-32 mRNA, suggesting the upregulation of postsynaptic
dopaminergic function. This finding is in contrast with a previous study
using unlesioned HDC KO mice, where no genotype differences were
found in these markers using in situ hybridization [27]. As in the present
study the mice were lesioned and administered dopaminergic drugs, the
increased mRNA levels in histamine-deficient mice could reflect pro-
cesses unique to the parkinsonian and levodopa-treated condition.
mRNA levels were unchanged by the lesion itself, possibly due to re-
versal of any changes by the dopaminergic drug treatment [28].
In naïve HDC KO mice, depolarization-induced [3H]dopamine re-
lease from striatal synaptosomes was increased, indicating presynaptic
alterations resulting in increased dopamine release. This result is in line
with previous studies on striatal dopamine and metabolite tissue con-
centrations suggesting increased dopamine turnover in HDC KO mice
[22,29], as well as our own similar tissue concentration findings (un-
published). Note that due to the continuous superfusion histamine is
not significantly present in the synaptosomal assay in either HDC KO or
WT preparations. Considering this isolated nature of the synaptosomal
preparation, the presynaptic alterations observed are likely to be long-
term consequences of the lack of histamine. Interestingly, no genotype
difference was observed in amphetamine-induced [3H]dopamine re-
lease. The increased responsiveness to amphetamine observed in the
HDC KO mice was thus unlikely to be mediated directly at the pre-
synaptic sites of amphetamine’s mechanisms of action.
Striatal H3R mRNA levels were increased in HDC KO mice, in line
with a previous report [30]. Although H3R upregulation has been
previously observed in Parkinson’s disease patients [7] and in
6−OHDA-lesioned rats [31], we observed no statistically significant
difference in H3R mRNA between the lesioned and intact hemispheres.
Striatal expression of 5-HT2A receptor mRNA was unchanged by the
lack of histamine or the dopaminergic lesion.
The present biochemical findings of increased release of dopamine
Fig. 3. Characterization of neurotransmitter function in HDC KO mice. A:
Striatal mRNA levels of neurotransmitter biomarkers in the intact and lesioned
hemispheres of mice with unilateral dopaminergic lesions. The expression of
mRNA for D1R, D2R, DARPP-32 and H3R was increased in HDC KO mice. Mean
of relative expression+ SEM shown, nWT=8–9, nKO= 8. B–C: Stimulated [3H]
dopamine release from striatal synaptosomes from unlesioned mice.
Depolarization-stimulated [3H]dopamine release (B) was significantly in-
creased in HDC KO animals. However, the lack of histamine had no effect on
half-maximal (0.5 μM) or maximal (10 μM) amphetamine (AMP)-induced [3H]
dopamine release (C). Mean stimulated release+ SEM shown, nWT=5,
nKO= 6, four replicates per mouse. *p < 0.05, ***p < 0.001, 2-way RM
ANOVA; **p < 0.01, t-test.
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and increased expression of dopamine receptor and DARPP-32 mRNA
suggest that the lack of brain histamine in HDC KO mice results in
significant pre- and postsynaptic upregulation of striatal dopaminergic
neurotransmission. Furthermore, the novel behavioral finding of in-
creased hemiparkinsonian motor dysfunction in HDC KO mice could
indicate that the alterations in dopaminergic activity are significant
enough to be reflected in changes in motor behavior. While parkin-
sonism is characterized by a lack of striatal dopamine, enhanced do-
paminergic function would not necessarily be beneficial, given the
fundamental role of irregular dopamine release in e.g., LID. Taken to-
gether, our findings, along with the previous literature, suggest a
complex histaminergic modulation of nigrostriatal dopaminergic neu-
rotransmission in both healthy and parkinsonian conditions. This in-
terplay may be significantly affected by dopaminergic denervation and
can be altered, potentially disruptively, by a lack of histamine and thus
quite possibly also other changes in the histaminergic system.
In conclusion, the study revealed important aspects on how the
neuronal histaminergic system influences the dopaminergic system in
the rodent brain, and represents new evidence for the complex interplay
between the two neurotransmitter systems within the nigrostriatal
pathway. Further studies, such as in vivo microdialysis experiments
measuring dopamine directly in the striatum of intact and lesioned
animals, could reveal in more detail how the lack of histamine alters
striatal dopamine neurotransmission in the healthy and parkinsonian
brain. Finally, the findings raise hope that further investigation of the
histaminergic system in Parkinson’s disease could shed new light on the
mechanisms of the disease and suggest potential new treatments.
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